COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02868190
Recruitment Status : Unknown
Verified December 2017 by Glaukos Corporation.
Recruitment status was:  Active, not recruiting
First Posted : August 16, 2016
Last Update Posted : December 18, 2017
Information provided by (Responsible Party):
Glaukos Corporation

Brief Summary:
This study objective is to evaluate the intraocular pressure (IOP) lowering effect of two trabecular micro-bypass stents (iStent inject) in eyes of subjects with primary open-angle glaucoma on one topical hypotensive medication

Condition or disease Intervention/treatment Phase
Open Angle Glaucoma Device: Two trabecular micro-bypass stents (iStent inject) Phase 4

Detailed Description:

The study design is as follows:


Subjects with medicated IOP > 18 mmHg and ≤ 30 mmHg

Subjects on one topical ocular hypotensive medication prior to stent implantation

Implantation of two iStent devices (if IOP is < 6 mmHg, at any point during the postoperative follow-up, medication will not be prescribed or will be discontinued)

IOP will be measured by two (2) observers to minimize bias; observer 1 will look through the slit lamp and turn the dial with readings being masked, and observer 2 will document the IOP

Diurnal IOP measurements

Follow-up through 60 months postoperative (but could be up to 61 months if subject needs to undergo terminal washout)

Descriptive statistics will be tabulated

Medical therapy considered necessary for the subject's welfare can be implemented at any time during the study at the investigator's discretion

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject)
Study Start Date : March 2013
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : May 2019

Arm Intervention/treatment
Two micro-bypass stents (iStent inject)
Standalone implantation of two trabecular micro-bypass stents (iStent inject)
Device: Two trabecular micro-bypass stents (iStent inject)
Standalone implantation of two trabecular micro-bypass stents (iStent inject)

Primary Outcome Measures :
  1. Mean intraocular pressure reduction of 20% or more vs baseline [ Time Frame: 12 months post-op ]

Secondary Outcome Measures :
  1. Proportion of subjects with intraocular pressure less than or equal to 18 mm Hg [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Screening Exam Inclusion Criteria:

  • Phakic patients or pseudophakic patients with posterior chamber intraocular lenses (PC-IOLs).
  • Primary open-angle glaucoma (including pigmentary or pseudoexfoliative).
  • Cup-to-disc ratio ≤ 0.9.
  • Visual field defects, or nerve abnormality characteristic of glaucoma.
  • One topical hypotensive medication at time of screening exam.
  • Intraocular pressure (IOP) > 18 mmHg and ≤ 30 mmHg (medicated) at screening exam.
  • Study eye BCVA 20/100 or better.
  • Normal angle anatomy as determined by gonioscopy.
  • Absence of peripheral anterior synechia (PAS), rubeosis or other angle abnormalities that could impair proper placement of stent.

Baseline Exam Inclusion Criteria:

  • Subject has completed appropriate medication washout.
  • Mean IOP > 22 mmHg and ≤ 38 mmHg after anti-glaucoma medication washout period.


Screening Exam Exclusion Criteria:

  • Aphakic patients or pseudophakic patients with anterior chamber IOLs (AC-IOLs).
  • Prior stent implantations (study eye).
  • Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders.
  • Functionally significant visual field loss, including severe nerve fiber bundle defects such as Bjerrum scotoma.
  • Prior incisional glaucoma surgery.
  • Prior SLT within 90 days prior to screening.
  • Prior ALT.
  • Iridectomy or laser iridotomy.
  • Ineligibility for ocular hypotensive medication washout period as determined by the investigator such as: visual field status would be placed at risk by washout period, or unmedicated IOP after washout period would be expected to exceed upper limit of ≥ 38 mmHg.
  • Any active corneal inflammation or edema (e.g., keratitis, keratoconjunctivitis, keratouveitis).
  • Clinically significant corneal dystrophy (e.g., bullous keratopathy, Fuch's dystrophy); any guttata.
  • Corneal surgery (prior or anticipated) of any type (including LASIK, LASEK, PRK, etc.) that may interfere with IOP measurement reliability.
  • Corneal opacities or disorders that would inhibit visualization of the nasal angle.
  • Congenital or traumatic cataract.
  • Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition.
  • Elevated episcleral venous pressure such as associated with: active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
  • Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.).
  • Chronic ocular inflammatory disease or presence of active ocular inflammation (e.g., uveitis, iritis, iridocyclitis, retinitis).
  • Pregnant or nursing women.

Baseline Exam Exclusion Criteria:

  • Subject did not complete medication washout.
  • Mean IOP < 22 mmHg or > 38 mmHg after anti-glaucoma medication washout.
  • Subject did not have a 3mmHg IOP increase over screening mean diurnal IOP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02868190

Layout table for location information
S.V. Malayan's Ophtalmology Centre
Yerevan, Armenia, 375108
Sponsors and Collaborators
Glaukos Corporation
Layout table for investigator information
Principal Investigator: Lilit Voskanyan, MD, PhD S.V. Malayan Eye Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Glaukos Corporation Identifier: NCT02868190    
Other Study ID Numbers: GCF-038
First Posted: August 16, 2016    Key Record Dates
Last Update Posted: December 18, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases